- Home
- SGMT vs ANIX Comparison
SGMT vs ANIX Comparison
Compare SGMT & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGMT
- ANIX
- Stock Information
- Founded
- SGMT 2006
- ANIX 1982
- Country
- SGMT United States
- ANIX United States
- Employees
- SGMT N/A
- ANIX N/A
- Industry
- SGMT
- ANIX Biotechnology: Pharmaceutical Preparations
- Sector
- SGMT
- ANIX Health Care
- Exchange
- SGMT Nasdaq
- ANIX Nasdaq
- Market Cap
- SGMT 269.2M
- ANIX 108.9M
- IPO Year
- SGMT 2023
- ANIX 1987
- Fundamental
- Price
- SGMT $9.40
- ANIX $3.17
- Analyst Decision
- SGMT Strong Buy
- ANIX Strong Buy
- Analyst Count
- SGMT 5
- ANIX 3
- Target Price
- SGMT $26.60
- ANIX $9.00
- AVG Volume (30 Days)
- SGMT 1.4M
- ANIX 126.1K
- Earning Date
- SGMT 08-13-2025
- ANIX 09-05-2025
- Dividend Yield
- SGMT N/A
- ANIX N/A
- EPS Growth
- SGMT N/A
- ANIX N/A
- EPS
- SGMT N/A
- ANIX N/A
- Revenue
- SGMT N/A
- ANIX N/A
- Revenue This Year
- SGMT N/A
- ANIX N/A
- Revenue Next Year
- SGMT N/A
- ANIX N/A
- P/E Ratio
- SGMT N/A
- ANIX N/A
- Revenue Growth
- SGMT N/A
- ANIX N/A
- 52 Week Low
- SGMT $1.73
- ANIX $2.07
- 52 Week High
- SGMT $10.43
- ANIX $4.20
- Technical
- Relative Strength Index (RSI)
- SGMT 61.34
- ANIX 48.74
- Support Level
- SGMT $8.49
- ANIX $3.18
- Resistance Level
- SGMT $9.98
- ANIX $3.24
- Average True Range (ATR)
- SGMT 0.76
- ANIX 0.14
- MACD
- SGMT -0.07
- ANIX -0.04
- Stochastic Oscillator
- SGMT 65.00
- ANIX 21.05
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.